Post on 17-Mar-2020
transcript
2009 Strategic Planning Meeting SNM Clinical Trials Network
Chicago, IL
Wednesday, September 30, 2009
AGENDA
Item Time Discussion
Leaders
BREAKFAST –
Welcome and Introductions 8:00am – 8:15 M. Graham
2009 Summary of Progress 8:15am – 9:30am M. Graham
Phantom Program P. Christian
Imaging Site Validation/Registry J. Hoffman
Education Programs M. Howlett
Database Committee J. Sunderland
Manufacturing Registry P. Conti
Questions and Discussion
BREAK 9:30am – 9:45am
Industry – Challenges/Lessons Learned 9:45am – 12:00pm P. Conti
Bristol-Myers Squibb: Observations Wendy Hayes
Isotope Shortage and Relevance to Clinical
Trials P. Conti
LUNCH 12:00pm – 1:00pm
Discussion of Next Multicenter IND 1:00pm – 2:00pm M. Graham
BREAK 2:00pm – 2:15pm
Three-Year Goals and Draft Work Plan 2:15pm – 4:00pm M. Graham
SNM Draft 3yr. Work Plan M. Ryan
Trial Design / Protocol Development P. Conti
A. Shields
Targets and Marketing of Network M. Ryan
Wrap-Up and Next Steps 4:00pm – 5:00pm P. Conti
2009 Summary of Progress
• First SNM multicenter IND for an investigational imaging biomarker
• First two founding members from the pharmaceutical development community on board
• 200+ members of both the imaging site and manufacturers registries
• Over 25% participation from outside the U.S.• Development and launch of a clinical oncology phantom
program• Many on-going educational activities to promote the
Network and advance the awareness and understanding of the “Practice of Clinical Trials” within the imaging community
Key Accomplishments
1. Organize multi-site clinical trials to gather standardized and harmonized imaging data that will lead to expanded use and validation of imaging biomarkers for therapeutic trials
2. Provide safety and efficacy data of imaging biomarkers through a centralized IND, potentially useful for eventual approval of such as as diagnostics
3. Organize a manufacturing registry for production of and access to imaging biomarkers
4. Provide a registry of qualified and certified imaging centers
Major Goals
Phantom Sub-Committee
Chair: Paul Christian, CNMT, BS, PET
Purpose:Management of phantom program for site qualification
Phantom Sub-Committee
Clinical Simulation Phantoms
Evaluate: Image performance-Acquisition-Processing-Interpretation
Lesion detectionSUV measurements
Purpose of PET phantom-Uniformity-Resolution -Contrast-Noise-Quantitative accuracy -PET/CT alignment-Attenuation correction
Accomplishments:1. Development of phantom qualification process2. Phantom acquisition3. Phantom review and quality assurance testing4. Administration of FLT, chest phantom demonstration
project
Phantom Sub-Committee
Submit Images and SUV Data
Site Phantom Qualification
PET Qualification Chest Phantom
0
0.5
1
1.5
2
2.5
3
3.5
0 1 2 3 4 5 6 7 8 9
Lesion Number
SU
Vm
ax
Series1Series2Series3Series4Series5Series6Series7
PET Qualification Chest Phantom
0
0.5
1
1.5
2
2.5
3
3.5
0 1 2 3 4 5 6 7 8 9
Lesion Number
SU
Vm
ax
Series1Series2Series3Series4Series5Series6Series7
PET Qualification Chest Phantom
0
0.5
1
1.5
2
2.5
3
3.5
0 1 2 3 4 5 6 7 8 9
Lesion Number
SU
Vm
ax
Series1Series2Series3Series4Series5Series6Series7
Assess:
Acquisition protocolAccuracy of doseReconstruction/filterImage qualityPET/CT alignmentAttenuation correctionImage noiseImage contrastMD visual assessmentLesion detectabilitySUV accuracyDICOM transfer validValidation of SUV DICOM
2010 Goals:1. Streamline phantom qualification program2. Develop process for long term maintenance and
administration of phantom site qualification3. Develop additional phantom programs including brain
and cardiac
Phantom Sub-Committee
Site Validation and Monitoring Committee
Chair: John M. Hoffman, M.D.
Purpose:• Development and management of imaging site
qualification and validation program• Develop a process whereby pharmaceutical partners
have the information to make decisions about which imaging sites have the infrastructure, resources, experience, and knowledge to perform imaging as it relates to pharmaceutical trials
Site Validation and Monitoring Committee
Accomplishments:1. Development of site qualification and validation process
including:– Available imaging equipment inventory for trials– Assessment of quality assurance programs in place at sites– Review of personnel and their qualifications– Evaluation of research related training of all personnel at site– Assessment of experience of site to perform imaging on therapeutic
trials – Regulatory infrastructure in place to perform imaging studies
2. Development and refinement of site qualification and validation forms
3. Process for evaluation of site “credentials”
Site Validation and Monitoring Committee
2010 Goals:1. Streamline site qualification and validation program
• Move to a web based process to obtain information• Beta and several other site validation of the process• Work with pharma to assure that the “required information” is
being obtained for this important process
2. Develop process for long term maintenance and administration of site qualification and validation process
3. Develop rating system for evaluation of imaging sites?4. Work with pharmaceutical partners to refine the process
to assure that the needed information is being assessed for partner to best choose sites for imaging
Site Validation and Monitoring Committee
Site Validation and Monitoring Committee
Education Update
• Standardization across clinical sites
• Research related training for technologists– Good Clinical Practice in Research– Imaging specific
Summary of Identified Needs
1. Develop a certificate program for technologists to
be trained in running clinical trials/clinical research
programs
– Create curriculum outline– Prepare presentations, videos, or webinar
presentations to cover all pertinent content with personnel
– Develop tracking metrics to verify completion of training by individuals
Development Plans
2. Provide research (imaging specific) training
materials to potential trial site personnel in registry
– Create curriculum outline– Prepare presentations, videos, or webinar
presentations to cover all pertinent content with personnel– Develop tracking metrics to verify completion of training by
individuals– Develop feedback mechanism for ongoing review
and improvement of presentations and materials
***This task assigned to Tech Educator Sub-Committee
Development Plans
3. Create enduring materials for use at clinical trial sites to provide reinforcement of educational programs– Online webinars available year round– Educational booklets– Poster presentations at sectional meetings– DVDs
Development Plans
4. Explore collaboration with research organizations that currently provide research related training– ACRP (Clinical Research Coordinator Training)– Drug Information Association (DIA)
Development Plans
5. Develop physician oriented clinical research programs to include the following components:
– FDA approval process– Review of Good Clinical Practice– Quality assurance in medical trials
Development Plans
Tech Educators Sub-Committee
Education Update
Courses for Technologists:
1. Focus on CTN 106: “Stick to it: Camera and Radiopharmacy” (2 Hour)
2. Focus on CTN 107: “O Say can I See your QC” (1 Hour)3. Focus on CTN 108: “The Importance of SOPs in Clinical
Trials” (1 Hour)
Educational Offerings
All courses offered online (continuous) and at SNM meetings
Timelines:• August 31 – First Draft of Courses due• September 14 – Proof reading complete• September 30 – Group review of courses• October 30 – Final Format of Courses• November 15 – Completion of VOICE and CEU credits• November 15 – Completion of Pre/Post Assessments• November 30 – Completion of final web format• December 15– Courses go live on CTN
Educational Offerings
1. Online educational offerings for technologists (continual)
2. Live course presentations at meetings3. Brochures and poster presentations at sectional
meetings
Delivery Channels
• Panel 1: Potential Role of Imaging Biomarkers in Development of Neurological Therapeutics
• Panel 2: A Regulatory Perspective on the Challenges of Standardization and Harmonization in Multicenter Imaging Clinical Trials
• Panel 3: Removing the Barriers to Use Imaging Biomarkers in Clinical Research : Progress of the SNM Clinical Trials Network
CMOD
Plans for Meetings
WMIC
Introduction to the SNM Clinical Trials NetworkGeorge Mills, MD, MBA
Distributed Manufacturing of PET Radiopharmaceuticals and Multicenter Clinical Trials Participation
Sally Schwarz, PhD, Washington University
Development of New Imaging Approaches for Drug Development and Treatment Monitoring
Anthony Shields, MD, PhD
Plans for Meetings
Plans for Meetings
Summit 2010: Molecular Imaging in Clinical Trials
SNM Mid-Winter Meeting
Session I – Current Challenges of Imaging in
Therapeutic Clinical Trials
Session II – Critical Elements of Imaging in High
Quality Multicenter Clinical Research
Database Sub-Committee
Chair: John Sunderland, Ph. D.
Purpose:• Development of centralized database to incorporate:
– Imaging site registrations– Radiopharmaceutical manufacturer registrations– Site validation
• Optimize database to maximize utility of CTN for Pharma, SNM, and other stakeholders
Database Sub-Committee
Accomplishments:
1. Database design
1. Integration of Clinical Trial Network Database with SNM Membership Database
1. First iteration of the Clinical Trials Network Database web application for data entry completed
Database Sub-Committee
CTN Database Structure and Flow
2010 Goals:
1. Complete database for full scale launch
1. Deliver database to SNM for long term maintenance
1. Fine-tune database entry
2. Finalize standard database reports
Database Sub-Committee
Manufacturing Registry Sub-CommitteeSeptember 30, 2009
Chair: Sally Schwarz, MS, RPh, BCNP Charge:
– Generation I (2009) – includes Europe• Define detailed input required for manufacturers database• Provide guidance to manufacturer's related to different pathways available
for IND participation• Collect data from at least 100 sites• Demonstrate ability to generate "pick-list" reports for a drug trial sponsor
– Generation II (2010) – expand to Asia• Maintain the current database (and grow)• Generate recommendations from the manufacturer's community to the SNM
related to future potential NDAs and future access and license fees.
Manufacturing Registry Sub-Committee
Accomplishments:1. Development of manufacturers registry
– 202 sites registered– 134 U.S.– 48 Europe– 20 Other
2. Promotion of integrated manufacturing group3. Provided ongoing education through Webinars and
Annual and Midwinter meetings
Manufacturing Registry Sub-Committee
2010 Goals: Generation II
1. Work with the Database Subcommittee to launch the second phase of the database allowing more detailed manufacturing input for registered sites
2. Lead educational process for CMP part 212 regulation3. Foster working relationships between manufacturers4. Develop GMP audit program for participating
manufacturing sites5. Expand manufacturing sites in Asia6. Get Pharma involved in the next IND choice
Manufacturing Registry Sub-Committee
CTN Strategic Planning Committee
Wendy HayesSusan GalbraithLinda VelasquezOncology Discovery Medicine & Clinical BiomarkersBristol-Myers Squibb
Chicago, 30 September 2009
Network IND
• Network IND – tracer/countries• Streamlined?• Is there a process presently in place?• Specifics – once identified – what happens/steps• Status – BMS updated on regular basis (website?)• Once approved – are guidelines available to help sites
(cross reference), health authorities (all countries), etc.• Feedback loop - process for addressing issues
– FAQ, Lessons learned
Registry of Qualified Imaging Sites
• Key – acceptance by Imaging Core Labs/Academic Centers/Scientific community
• Future Phase III trials (community based practice/academic centers)• SNM – site list available for ‘public’
• Align with Netherlands (VUMC)?• What is the qualification process?
• Phantoms? • All therapeutic areas (NS, CV)
• Length of qualification – maintenance/ongoing QC• Documentation – access by core labs
• Process for sharing – BMS – gatekeeper?• Formal request process?
• Collaboration with BMS preferred providers for acceptance of qualification –open to discussion?
Access to Phantom Program
• SNM Vision?
Registry of Manufacturers
• Access to new tracer development• How will the registry of manufacturers work?
• Qualification• List of available tracers• Areas of interest for future collaboration (NS, Immunology)
Access to SNM Standardized Protocols
• Status of development• Alignment with other efforts/consortia
• CTSA?• QIBA?• ADNI?• Academia?
• Assess once finalized – website?• Feedback loop
Study Specific Protocol and Review
• SNM Vision?
Additional Issues
• Tracer shortages – FDA/Health Authority Guidelines
• Response Criteria – new tracers/FLT-PET• Network of Phase I units/Imaging Centers – NS
– Sites, tracers, patient population, regulatory timelines, throughput
• Late phase – plans for nonacademic centers
Isotope Shortage Update
Survey completed with help from the National Association of Nuclear Pharmacies
(NANP)
Two Main Generators Currently Non-functioning
• National Research Universal (NRU) Reactor in Chalk River Canada,
• High Flux Reactor (HFR), in Petten, The Netherlands.
Survey completed with help from the National Association of Nuclear Pharmacies
(NANP)
Isotope Shortage
• 59.77% pharmacies affected by molybdenum-99 shortage• Only 29.31% have access to an alternate source of
99Mo/99mTc generators• Percentage of 99mTc radiopharmaceuticals able to be
filled:– 0-25%: 6.32% – 26-50%: 14.37% – 52-75%: 20.69% – 76-100%: 18.97%
Isotope Shortage Survey Final Results
August 10, 2009
Survey completed with help from the National Association of Nuclear Pharmacies (NANP)
Changes Made in Response to Shortage
• Reschedule of patient orders to another day or time 76.29% • Cancellation of orders: 64.95% • Change in radiopharmaceutical used: 82.47% • Decrease in dosage: 81.44% • Cancelled backup doses: 71.13% • No bulk orders: 81.44% • Changed delivery schedules: 71.13% • Eliminated standing order: 68.04% • Shifted dosing times: 58.76% • Eluting older generators more often: 84.54% • Modified preparation: 34.02% • Sent doses with later calibration times: 21.65% • Delay and divide deliveries: 65.98% • Eliminate all contingency doses: 63.92%
Isotope Shortage Survey Final Results
August 10, 2009
Survey completed with help from the National Association of Nuclear Pharmacies (NANP)
Alternate Radiopharmaceuticals Used:• TI-201 instead of Tc-99m agents for cardiac imaging:
82.47% • In-111 Oxine: 5.15% • FDG for bone imaging: 6.19% • Ga-67: 2.06% • N-13 ammonia: 1.03% • F-18 NaF: 9.28% • Other: 5.15%
Isotope Shortage Survey Final Results
August 10, 2009
Survey completed with help from the National Association of Nuclear Pharmacies (NANP)
Tracer Grid
TargetMolecular Process
Imaged/Mechanism
PET
IsotopeAgent Availability
# of Single
Site INDs
Pharm/Tox,
Dosimetry
and CMC
Status
Current Clinical
Trials (single
site? Under what
auspices?)
Reference Site /
PersonComment
HypoxiaInadequate blood
supply/oxygen to tumorF-18 F-MISO Investigational NCI-CIP IND published
Investigational
Clinical Trials
ACRIN
HypoxiaInadequate blood
supply/oxygen to tumorCu-64
Cu-64-
ATSMInvestigational yes yes
HypoxiaInadequate blood
supply/oxygen to tumorF-18 FAZA Investigational yes (at least 1)
Investigational
Clinical Trials/INDSandy McEwan
HypoxiaInadequate blood
supply/oxygen to tumorF-18 F-18 EF-5 Investigational yes (at least 1)
NCI/some (not
public?)In a Phase II trial
Varian
Biosynergy; U of
Penn & maybe
Duke
F2
Nucleophilic
Chemistry;
Limited
sources who
can produce.
Hypoxia: A major factor limiting the effectiveness of chemotherapy and radiotherapy in cancer treatment
F-18 misonidazole (F-18 MISO): A molecular imaging agent indicating the sensitivity of hypoxic tumors to the cytotoxic effects of ionizing
radiation.
Cu-64 copper(II)bis(thiosemicarbazone) (Cu-64 ATSM): A molecular imaging agent preferentially taken up by hypoxic cells. The retention
of this agent is inversely proportional to tissue oxygenation allowing quantification of tumor hypoxia with PET/CT
F18 fluoroazomycinarabinofuranoside (F-18 FAZA): A molecular imaging agent for the evaluation of tumor hypoxia and radiosensitivity
with PET/CT
F-18 etanidazole (F18 EF5): A molecular imaging agent for the evaluation of tumor hypoxia with PET/CT
28Sep09
SNM Clinical Trials NetworkDraft 3 Year Plan
1. Drive understanding of the importance and need for standardization and quantitation.
2. Create a community of trained, qualified, experienced Physicians, Scientists, and certified Molecular Imaging Research Technologists.
3. Deliver high quality programs & services. When necessary, sacrifice quantity for quality. Do less (perhaps) but do it well.
2010 Top 3
Critical-to-Success Factors
Goal Breakdown
Optimal Goal: Qualify (using phantom) and validate 25+ “preferred” sites worldwide over next 12-18 months
Action Plan:• Streamline phantom and validation programs• Identify Pharma “wish list” of targeted sites
• Target imaging sites based on location and capabilities• Develop brain and cardiac phantoms
Site Qualification and Validation
Goal: Consider submission of a multicenter IND every 12-18 months based on need and feasibility
Action Plan:• Identify next tracer according to industry demand• Complete regulatory filing• Make access to multicenter IND available to network
participants
IND Development
Goal: Develop Standardized Molecular Imaging Protocols
Action Plan:• Complete standardized FDG protocol• Refine template for standardized protocols• Continue to work towards development of additional
standardization at imaging sites• Develop additional FLT protocols• Continue to develop and submit one new tracer IND per
year
Standardized Protocols
Goal: Develop Network Workshops and Courses to Promote Standardization at Imaging Sites
Action Plan:• Develop and launch courses on standardization at imaging
sites• Promote clinical research education for physicians• Offer joint sessions at national meetings (CMOD, WMIC,
annual SNM categorical)• Consider offerings at other radiological and non-radiology
conferences (RSNA, ASCO, etc)
Training and Site Orientation
Goal: Promote Clinical Research Education for Molecular Imaging Technologists
Action Plan:• Develop and implement courses for Molecular Imaging
Research Technologists (MIRT) to include:– Standardization of imaging protocols– QA/QC at imaging research sites– Importance of SOPs in Research
• Develop certification program for MIRT
Training and Site Orientation
Goal: Develop integrated database to fulfill needs of the Network
Action Plan:• Launch multi-level database to include:
– Clinical research imaging site registry– Radiopharmaceutical manufacturer registry– Site validation and qualification results– Query mechanisms for benchmarking and outcomes– “Event-driven” audits and recertifying sites
Database
Goal: Communicate Need for Clinical Research Standardization at Imaging Sites
Action Plan:• Promote courses through regional SNM chapter meetings• Develop Network Newsletter• Publish “Critical Success” white papers
• Improve adaptation and integration with bio-imaging CROs• Update CTN website to include “members-only” access to
protocol templates, FAQs, education and site-to-site communications
Communication
Goal: Communicate Need for Clinical Research Standardization at Imaging Sites Internationally
Action Plan:• Expand site qualification and validation programs
internationally• Incorporate international markets into the Network• Expand course offerings• Course offerings at international meetings (EANM, etc.)• Promote increased international Network participation
Globalization Strategy
1. Drive understanding of the importance and need for standardization and quantitation.
2. Create a community of trained, qualified, experienced and certified Molecular Imaging Research Technologists.
3. Deliver high quality programs & services. When necessary, sacrifice quantity for quality. Do less (perhaps) but do it well.
2010 Top 3
Critical-to-Success Factors
Trial Design Committee
Chair: Anthony Shields, MD, Ph.D.
Purpose:Standardization of molecular imaging protocols and
development of centralized INDs.Assist in the development of clinical trials using imaging to:
1- Develop new therapeutic agents.2- Test and validate new imaging approaches.
Trial Design Committee
Accomplishments:• FDA approved FLT biomarker IND available for cross-
reference in pharmaceutical clinical trials• Standardized imaging protocols being developed
Trial Design Committee
Goals:1. Standardized imaging protocols including FDG2. Regulatory approval of additional biomarker INDs 3. Protocol development support for pharmaceutical trials
Trial Design Committee
Targets and Marketing of Network
The Network aims to target:• Radiopharmaceutical imaging sites• Physicians and Scientists participating (or desiring to
participate) in imaging trials• Molecular Imaging Research Technologists• Tracer manufacturers• Pharmaceutical companies performing imaging trials• Collaboration with CROs• Oncologists / clinical colleagues• Other imaging societies
Target Audience
Marketing Strategy
Strategy:• Maximize Network exposure through CTN and SNM
websites• Print advertisements in JNM and newsletters• Develop and offer courses in the conduct of clinical trials
at imaging sites through:– Webinars– Live presentations– Self-taught online courses
Communication
Strategy• Increase Network awareness through presence at
national and international meetings to include:
– SNM Annual categorical– SNM Mid-winter Meeting– Joint sessions with industry leaders (CMOD, WMIC, etc.)– EANM– SNM local Chapter meetings– Non-radiology conferences (ASCO)
Communication
Strategy• Utilize Network resources to publish white papers,
articles, and editorials on:
– Need for standardization at trial sites– Phantom qualification program– Site validation program– Conduct of clinical trials at imaging sites
Communication
Strategy:Pair with pharmaceutical companies to conduct trials
utilizing tracers which will incorporate:
• Standardized imaging protocols• Phantom qualification of sites• Ongoing site quality assurance
Clinical Trials
Discussion:
• How do we market to other pharma/bio companies?• How do we market to CROs? Offer non-imaging CROs help with what they don’t
want to do Write imaging protocols/guidelines Update them on our progress and available services Imaging CROs become “preferred” groups
recommended as “go to” for Pharma
Marketing Strategy